MedTrace Logo

MediHoney for Radiation Dermatitis

NCT02234479 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2020-03-18

Study results available
· View outcomes & findings →

Summary

The aim of this study is to compare the effects of Medihoney and Hydrophor on radiation dermatitis reactions in a group of women undergoing radiation therapy for breast cancer. It is hoped that the outcome of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis as well as sufficient preliminary data to expand this study to larger, federally funded research (R01) looking at the beneficial aspects of Medihoney across a spectrum of radiation dermatitis and mucositis in several disease settings.

Conditions

Interventions

BIOLOGICAL

Hydrophor (Group A)

* Rehydrates dry, chapped or chafed skin * May be used alone as a skin lubricant or protectant

BIOLOGICAL

MediHoney (Group B)

It helps the body's natural healing processes in three key ways which have been shown to have healing benefits: * Maintain a balanced environment for healing. * Aids in reducing dermatitis. * Reduce affected area pH.2-3

Sponsors & Collaborators

  • Integra LifeSciences Corporation

    collaborator INDUSTRY

  • University of Maryland, Baltimore

    lead OTHER

Principal Investigators

  • Elizabeth Nichols, MD · University of Maryland, College Park

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2014-11-30
Completion
2014-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02234479 on ClinicalTrials.gov